FI61688C - Foerfarande foer framstaellning av terapeutiskt anvaendbara oxminsyraderivat - Google Patents
Foerfarande foer framstaellning av terapeutiskt anvaendbara oxminsyraderivat Download PDFInfo
- Publication number
- FI61688C FI61688C FI662/74A FI66274A FI61688C FI 61688 C FI61688 C FI 61688C FI 662/74 A FI662/74 A FI 662/74A FI 66274 A FI66274 A FI 66274A FI 61688 C FI61688 C FI 61688C
- Authority
- FI
- Finland
- Prior art keywords
- mol
- give
- found
- title compound
- condensed
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 12
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 71
- -1 U-pyridyl Chemical group 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical class NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 5
- 150000002431 hydrogen Chemical group 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 238000000921 elemental analysis Methods 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- GUGQQGROXHPINL-UHFFFAOYSA-N 2-oxobutanoyl chloride Chemical compound CCC(=O)C(Cl)=O GUGQQGROXHPINL-UHFFFAOYSA-N 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 13
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000003266 anti-allergic effect Effects 0.000 description 8
- AQAHTARDEJNYPN-UHFFFAOYSA-N 2-amino-6-methoxybenzamide Chemical compound COC1=CC=CC(N)=C1C(N)=O AQAHTARDEJNYPN-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000000043 antiallergic agent Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 229960000265 cromoglicic acid Drugs 0.000 description 5
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 206010003645 Atopy Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- RZMZBHSKPLVQCP-UHFFFAOYSA-N ethyl 2-amino-2-oxoacetate Chemical compound CCOC(=O)C(N)=O RZMZBHSKPLVQCP-UHFFFAOYSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- GGLRYZACPLNCKB-UHFFFAOYSA-N ethyl 2-(2-carbamoyl-3-methoxyanilino)-2-oxoacetate Chemical compound CCOC(=O)C(=O)NC1=CC=CC(OC)=C1C(N)=O GGLRYZACPLNCKB-UHFFFAOYSA-N 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 2
- 206010045240 Type I hypersensitivity Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical class ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NPHULPIAPWNOOH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(2,3-dihydroindol-1-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCC2=CC=CC=C12 NPHULPIAPWNOOH-UHFFFAOYSA-N 0.000 description 1
- FNXZMHNQECQCNX-UHFFFAOYSA-N 2-amino-4-methoxybenzamide Chemical compound COC1=CC=C(C(N)=O)C(N)=C1 FNXZMHNQECQCNX-UHFFFAOYSA-N 0.000 description 1
- DNRVZOZGQHHDAT-UHFFFAOYSA-N 2-amino-5-chlorobenzamide Chemical compound NC(=O)C1=CC(Cl)=CC=C1N DNRVZOZGQHHDAT-UHFFFAOYSA-N 0.000 description 1
- SOBQOVZAFJDEJI-UHFFFAOYSA-N 2-amino-5-nitrobenzamide Chemical compound NC(=O)C1=CC([N+]([O-])=O)=CC=C1N SOBQOVZAFJDEJI-UHFFFAOYSA-N 0.000 description 1
- UKZLJOODAJZPCA-UHFFFAOYSA-N 2-amino-6-(2-phenoxyethoxy)benzamide Chemical compound NC(=O)C1=C(N)C=CC=C1OCCOC1=CC=CC=C1 UKZLJOODAJZPCA-UHFFFAOYSA-N 0.000 description 1
- PNFTUXAUQMEFRT-UHFFFAOYSA-N 2-amino-6-butoxybenzamide Chemical compound CCCCOC1=CC=CC(N)=C1C(N)=O PNFTUXAUQMEFRT-UHFFFAOYSA-N 0.000 description 1
- RMDBIAFBDRRSOK-UHFFFAOYSA-N 2-amino-6-chlorobenzamide Chemical compound NC(=O)C1=C(N)C=CC=C1Cl RMDBIAFBDRRSOK-UHFFFAOYSA-N 0.000 description 1
- DDSVLHMQRQQNHI-UHFFFAOYSA-N 2-amino-6-ethoxybenzamide Chemical compound CCOC1=CC=CC(N)=C1C(N)=O DDSVLHMQRQQNHI-UHFFFAOYSA-N 0.000 description 1
- LBVLXRZXEOPYDW-UHFFFAOYSA-N 2-amino-6-methoxybenzonitrile Chemical compound COC1=CC=CC(N)=C1C#N LBVLXRZXEOPYDW-UHFFFAOYSA-N 0.000 description 1
- PYNMWBAZBVWELD-UHFFFAOYSA-N 2-amino-6-propan-2-yloxybenzamide Chemical compound CC(C)OC1=CC=CC(N)=C1C(N)=O PYNMWBAZBVWELD-UHFFFAOYSA-N 0.000 description 1
- OLGPJUANLIYSDC-UHFFFAOYSA-N 2-amino-6-propoxybenzamide Chemical compound CCCOC1=CC=CC(N)=C1C(N)=O OLGPJUANLIYSDC-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- QIKYZXDTTPVVAC-UHFFFAOYSA-N 4-Aminobenzamide Chemical compound NC(=O)C1=CC=C(N)C=C1 QIKYZXDTTPVVAC-UHFFFAOYSA-N 0.000 description 1
- UTKUVRNVYFTEHF-UHFFFAOYSA-N 4-nitro-3-(trifluoromethyl)aniline Chemical compound NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 UTKUVRNVYFTEHF-UHFFFAOYSA-N 0.000 description 1
- QPQKUYVSJWQSDY-UHFFFAOYSA-N 4-phenyldiazenylaniline Chemical compound C1=CC(N)=CC=C1N=NC1=CC=CC=C1 QPQKUYVSJWQSDY-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000794 anti-serotonin Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- IDMMJHZAWXBGBL-UHFFFAOYSA-N butan-2-yl 2-amino-2-oxoacetate Chemical compound CCC(C)OC(=O)C(N)=O IDMMJHZAWXBGBL-UHFFFAOYSA-N 0.000 description 1
- JQOLMUGUXNNIOR-UHFFFAOYSA-N butyl 2-amino-2-oxoacetate Chemical compound CCCCOC(=O)C(N)=O JQOLMUGUXNNIOR-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- GYFAUGCHIXCGOJ-UHFFFAOYSA-N cyclohexyl 2-amino-2-oxoacetate Chemical compound NC(=O)C(=O)OC1CCCCC1 GYFAUGCHIXCGOJ-UHFFFAOYSA-N 0.000 description 1
- GCFAUZGWPDYAJN-UHFFFAOYSA-N cyclohexyl 3-phenylprop-2-enoate Chemical compound C=1C=CC=CC=1C=CC(=O)OC1CCCCC1 GCFAUZGWPDYAJN-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- YDGAUBHNAKCSKF-UHFFFAOYSA-N ethyl 2-anilino-2-oxoacetate Chemical compound CCOC(=O)C(=O)NC1=CC=CC=C1 YDGAUBHNAKCSKF-UHFFFAOYSA-N 0.000 description 1
- DSMSFNNXCMCOLU-UHFFFAOYSA-N ethyl 2-oxo-2-(pyridin-3-ylamino)acetate Chemical compound CCOC(=O)C(=O)NC1=CC=CN=C1 DSMSFNNXCMCOLU-UHFFFAOYSA-N 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- AEVHVVDLIHWAGR-UHFFFAOYSA-N methyl 2-amino-2-oxoacetate Chemical compound COC(=O)C(N)=O AEVHVVDLIHWAGR-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical group COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- PSYJOBOWPNKDLG-UHFFFAOYSA-N n'-(2-carbamoyl-3-methoxyphenyl)oxamide Chemical compound COC1=CC=CC(NC(=O)C(N)=O)=C1C(N)=O PSYJOBOWPNKDLG-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940006070 other antiallergics in atc Drugs 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- JUIAYHVRSGDQRC-UHFFFAOYSA-N propan-2-yl 2-amino-2-oxoacetate Chemical compound CC(C)OC(=O)C(N)=O JUIAYHVRSGDQRC-UHFFFAOYSA-N 0.000 description 1
- XJUSRAJAEPIPIY-UHFFFAOYSA-N propyl 2-amino-2-oxoacetate Chemical compound CCCOC(=O)C(N)=O XJUSRAJAEPIPIY-UHFFFAOYSA-N 0.000 description 1
- GNQKVUBKAJESQJ-UHFFFAOYSA-N propyl 2-oxo-2-(pyridin-2-ylamino)acetate Chemical class CCCOC(=O)C(=O)NC1=CC=CC=N1 GNQKVUBKAJESQJ-UHFFFAOYSA-N 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
- C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
- C07C245/08—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34446673A | 1973-03-23 | 1973-03-23 | |
| US34446673 | 1973-03-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI61688B FI61688B (fi) | 1982-05-31 |
| FI61688C true FI61688C (fi) | 1982-09-10 |
Family
ID=23350656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI662/74A FI61688C (fi) | 1973-03-23 | 1974-03-06 | Foerfarande foer framstaellning av terapeutiskt anvaendbara oxminsyraderivat |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS5920664B2 (en, 2012) |
| AR (1) | AR207563A1 (en, 2012) |
| BE (1) | BE812743A (en, 2012) |
| CA (1) | CA1034118A (en, 2012) |
| CH (1) | CH612914A5 (en, 2012) |
| DE (1) | DE2413966A1 (en, 2012) |
| EG (1) | EG11281A (en, 2012) |
| ES (1) | ES424514A1 (en, 2012) |
| FI (1) | FI61688C (en, 2012) |
| FR (1) | FR2222097B1 (en, 2012) |
| NL (1) | NL7403843A (en, 2012) |
| PH (1) | PH14870A (en, 2012) |
| SE (1) | SE411898B (en, 2012) |
| ZA (1) | ZA74635B (en, 2012) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4011337A (en) * | 1975-07-07 | 1977-03-08 | The Upjohn Company | Oxamide-oxamic compounds, compositions and methods of use |
| US4172147A (en) * | 1976-11-17 | 1979-10-23 | The Upjohn Company | 3,5-Dinitro oxanilic acid ester compounds, compositions and methods |
| US4119783A (en) * | 1977-02-18 | 1978-10-10 | The Upjohn Company | 3'Lower alkylcarbonyl oxanilic acid esters |
| NL7810634A (nl) * | 1977-10-28 | 1979-05-02 | May & Baker Ltd | Tetrazool-derivaten. |
| DE3027528A1 (de) * | 1980-07-19 | 1982-02-18 | Basf Ag, 6700 Ludwigshafen | Ueberbrueckte thiazolyloxamidsaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel |
| DE3027527A1 (de) | 1980-07-19 | 1982-02-18 | Basf Ag, 6700 Ludwigshafen | Neue oxamidsaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel |
| DE3135250A1 (de) * | 1981-09-05 | 1983-03-17 | Basf Ag, 6700 Ludwigshafen | Tricyclische thiazolyloxamate, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel |
| FR2546885B1 (fr) * | 1983-06-06 | 1986-02-07 | Fabre Sa Pierre | Oxamates d'anthranilates fonctionnalises utiles comme medicaments dans le traitement des dermatoses inflammatoires |
| JPS6112268U (ja) * | 1984-06-25 | 1986-01-24 | 松下電工株式会社 | プリント配線基板 |
| JPH072697B2 (ja) * | 1985-05-24 | 1995-01-18 | 久光製薬株式会社 | 新規なオキサニル酸誘導体 |
| WO1999046236A1 (en) * | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| US6225329B1 (en) | 1998-03-12 | 2001-05-01 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPases) |
| EP2033688B1 (de) | 2007-08-20 | 2012-10-17 | Symrise AG | Oxalsäurederivate und deren Verwendung als physiologische Kühlwirkstoffe |
-
1974
- 1974-01-01 AR AR252822A patent/AR207563A1/es active
- 1974-01-30 ZA ZA00740635A patent/ZA74635B/xx unknown
- 1974-03-04 PH PH15573A patent/PH14870A/en unknown
- 1974-03-06 FI FI662/74A patent/FI61688C/fi active
- 1974-03-20 EG EG86/74A patent/EG11281A/xx active
- 1974-03-21 NL NL7403843A patent/NL7403843A/xx not_active Application Discontinuation
- 1974-03-22 CA CA195,729A patent/CA1034118A/en not_active Expired
- 1974-03-22 FR FR7409903A patent/FR2222097B1/fr not_active Expired
- 1974-03-22 SE SE7403941A patent/SE411898B/xx unknown
- 1974-03-22 CH CH405374A patent/CH612914A5/xx not_active IP Right Cessation
- 1974-03-22 BE BE142383A patent/BE812743A/xx not_active IP Right Cessation
- 1974-03-22 DE DE2413966A patent/DE2413966A1/de not_active Ceased
- 1974-03-22 ES ES424514A patent/ES424514A1/es not_active Expired
- 1974-03-23 JP JP49033104A patent/JPS5920664B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2222097A1 (en, 2012) | 1974-10-18 |
| EG11281A (en) | 1977-05-31 |
| BE812743A (fr) | 1974-09-23 |
| AU6575374A (en) | 1975-08-21 |
| CH612914A5 (en) | 1979-08-31 |
| CA1034118A (en) | 1978-07-04 |
| SE411898B (sv) | 1980-02-11 |
| JPS49135929A (en, 2012) | 1974-12-27 |
| ES424514A1 (es) | 1976-06-16 |
| PH14870A (en) | 1982-01-08 |
| ZA74635B (en) | 1975-09-24 |
| DE2413966A1 (de) | 1974-09-26 |
| FI61688B (fi) | 1982-05-31 |
| JPS5920664B2 (ja) | 1984-05-15 |
| NL7403843A (en, 2012) | 1974-09-25 |
| AR207563A1 (es) | 1976-10-15 |
| FR2222097B1 (en, 2012) | 1978-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3966965A (en) | Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions | |
| FI61688C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara oxminsyraderivat | |
| US4069343A (en) | Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions | |
| CY1446A (en) | Chemical compounds derived from cyclobutene | |
| US4057632A (en) | Method of treatment using tetrazole-5-carboxamide derivatives | |
| US4036837A (en) | 2 Alkoxyoxamoyl-pyrazines | |
| US4054666A (en) | Compositions and methods of treating immediate hypersensitivity reactions with thiazolyl oxamic acid derivatives | |
| JPS5946220B2 (ja) | 複素環化合物の製法 | |
| US4110453A (en) | N-(2-pyrimidinyl)1h-(or 2h)tetrazole-5-carboxamide derivatives for the prevention of immediate type hypersensitivity reactions | |
| US4044144A (en) | 1H-tetrazole-5-carboxamides | |
| US4082751A (en) | Therapeutic agents | |
| US4096153A (en) | Arylene-bis-tetrazole-5-carboxamides | |
| US4160100A (en) | Oxamic acid derivatives | |
| US4191840A (en) | Oxamic acid derivatives | |
| US4154961A (en) | Oxamic acid derivatives | |
| US3937719A (en) | (4-oxo-4h-1-benzopyran-2-yl)-oxamic acid, salts and esters anti-allergic agents | |
| CA1071203A (en) | Aromatic amidines as antiviral agents in animals | |
| US4625028A (en) | 6-aryluracils and selected novel intermediates used in the preparation thereof | |
| US4110458A (en) | N-(pyridyl) oxamic acid derivatives | |
| US4171367A (en) | Pyrazolyl amino imidazolines | |
| US4054657A (en) | Pyrimidinyl oxamic acids and esters, and compositions and methods for the suppression of allergic manifestations | |
| EP0064385B1 (en) | 2,6-diaryl-pyridinecarboxylic acids and their therapeutic utility | |
| US4054661A (en) | Pyridyl oxamic acid derivatives and use in the prevention of allergic reactions | |
| US4087606A (en) | 2-Cyano-3- or 4-(substituted amino)oxanilic acid derivatives | |
| US3989835A (en) | Method of using 6-substituted amino phenyl-2,3,5,6-tetra-hydro[2,1-b]thiazoles for controlling gastrointestinal nematodes |